Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Magic mushroom therapy tested for veteran PTSD

NCT ID NCT05554094

Symptom relief Sponsor: Ohio State University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether psilocybin, the active ingredient in magic mushrooms, can safely help veterans with PTSD. Fifteen veterans will receive two doses of psilocybin in a supervised therapy setting. Researchers will monitor side effects and measure changes in PTSD symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
psilocybin
What this could lead to
If it works, this could point toward a new treatment option for PTSD in veterans, potentially easing symptoms like flashbacks and anxiety.
What could go wrong
This is a very small, early-stage trial with only 15 people and no placebo group. Results may not apply to all veterans, and psilocybin can cause temporary psychological distress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2023

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 64 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

In order to be eligible to participate in this study, an individual must meet all of the following criteria: * A US military Veteran * 21 to 64 years old * Have at least a high-school level of education or equivalent. * Have a current DSM-5 diagnosis of Post-Traumatic Stress Disorder * Have a CAPS-5 total severity score of ≥35 at baseline * No antidepressant medications prior to enrollment * Be judged by study team clinicians to be at low risk for suicidality * Be medically stable * Have limited lifetime use of hallucinogens General medical exclusion criteria: * Women who are pregnant * Cardiovascular conditions * Epilepsy with history of seizures * Insulin-dependent diabetes * Currently taking psychoactive prescription medication * Currently taking on a regular (e.g., daily) basis any medications having a primary centrally-acting serotonergic effect, including Monoamine oxidase inhibitors.. Psychiatric Exclusion Criteria: * Current or past history of schizophrenia or other psychotic disorders or Bipolar I or II Disorder * Current or history within one year of a moderate or severe alcohol, tobacco, or other drug use disorder * Have a first or second-degree relative with schizophrenia spectrum or other psychotic disorders or Bipolar I or II Disorder * Has a psychiatric condition which precludes the establishment of therapeutic rapport * History of a medically significant suicide attempt * Current antidepressant use

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mental disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute stress disorder mental disorder post-traumatic stress disorder psychiatric disorder Stress Disorders, Traumatic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mental disorder PTSD Stress disorders, post-traumatic Stress disorders, traumatic Trauma and stressor related disorders

Contacts and locations

Locations

  • Ohio State University Department of Psychiatry and Behavioral Health at the Davis Medical Research Center

    Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.